Trial Condition(s):
Advanced or recurrent solid tumor harboring an NTRK gene fusion
An observational study to learn more about NTRK gene fusion positive in Solid Tumor in Japan
Bayer Identifier:
22415
ClinicalTrials.gov Identifier:
EudraCT Number:
Not Available
EU CT Number:
Not Available
Trial Purpose
This is an observational study in which data from the past of people with solid tumors harboring an NTRK gene fusion in Japan are studied. In observational studies, only observations are made without specified advice or interventions.
Advanced or recurrent solid tumor harboring an NTRK gene fusion is a rare type of solid cancer caused by specific changes in the genes called NTRK gene fusion, and which has spread to nearby tissues and/or lymph nodes or has returned. Due to this change in the gene, an altered protein known as a TRK fusion protein is made, which can cause cancer cells to grow and survive.
The main purpose of this study is to learn more about NTRK gene fusion in people in Japan. To do this, researchers will collect information on the number or percentage of Japanese people with NTRK gene fusion in any solid tumor.
The data will come from the national database called C-CAT. They will cover the period from June 2019 until January 2023.
Besides this data collection, no further tests or examinations are planned, and no visits are required in this study.
Inclusion Criteria
- Patients with any solid tumor and genome profiling results
Exclusion Criteria
- None
Trial Summary
Enrollment Goal
Trial Dates
Phase
Could I receive a placebo?
Products
Accepts Healthy Volunteers
Where to Participate
| Locations | |
|---|---|
Locations Many Locations Many Locations, Japan | Contact Us: E-mail: [email protected] Phone: (+)1-888-84 22937 |
Trial Design
A Retrospective Observational Study to Investigate the Prevalence of NTRK gene fusion positive in Solid Tumor in Japan
Trial Type:
Observational
Intervention Type:
Other
Trial Purpose:
N/A
Allocation:
N/A
Blinding:
N/A
Assignment:
N/A
Trial Arms:
1
Primary Outcome
- Prevalence of patients with NTRK gene fusions by patient characteristic categories, such as tumor typesTimeframe: Retrospective data analysis from June 2019 to the latest data available (planned end of February 2023)
- Distribution of cancer types in patients with NTRK fusion positive among all, adult and pediatricTimeframe: Retrospective data analysis from June 2019 to the latest data available (planned end of February 2023)
Additional Information
Copyright © Bayer
Powered by
